Our research group has characterized the preclinical activity of PHY906 as a modulator of cytotoxicity of anticancer agents as well as a cytoprotective agent of chemotherapy. In this project, we are addressing an important hypothesis, as suggested by our preliminary pre-clinical results, that part of the mechanism for the biological activity of PHY906 involves the modulation of certain key immuoregulatory processes and metabolic functions of tumor and normal tissues, which will be reflected in the immunokine/growth factor and metabolomic profiles from plasma of patients under treatment. We hope to identify the relevant potential biomarkers that can be used to predict the subset of patients who may benefit from the use of PHY906 using multiplex approach. The proposed studies will also to begin indentify the potential multiple sites of action and bioactive compounds of this herbal medicine. This Project has two specific aims:
Specific Aim 1 will investigate the potential biomarkers in plasma that can be used to correlate the effect of PHY906 with clinical benefit of irinotecan-based chemotherapy, either toxicity or clinical activity, in patients with metastatic colorectal cancer. For these studies, a broad series of biomarker analyses will be conducted, and they include the following: profiles of immunocytokines, chemokines, growth factors; metabolomic profiles including steroid hormones; levels of tumor DNA and mutational load distribution analysis as determined by presence of mutations of K-Ras, B-Raf, or PI3K/Akt from tumor DNA in plasma.
Specific Aim 2 will investigate the bioactive compounds involved in the action of PHY906 on immunological regulatory pathways.
This aim will characterize the chemical profile of PHY906 and their metabolites in each sample taken from patients using LC/MS spectrometry and correlate each plasma's activity against several immunological regulatory signal pathways and DNA repair pathways ex vivo with the goal of identifying bioactive compounds in plasma. The first specific aim may show how PHY906 works from a systems biology point of view, and these studies may also have a general impact on the correlation of those biomarkers with clinical outcomes for other cancer treatments. The second specific aim will confirm our preclinical studies of PHY906, and more importantly, establish new methodologies to identify bioactive candidate compounds for their potential biological actions. This Project is highly and tightly integrated with the other two proposed Projects in this Program, and the information obtained from this work may serve as a novel paradigm for combining Chinese herbal medicine with conventional cancer chemotherapy to treat human cancers.

Public Health Relevance

The proposed study could open a new paradigm for cancer chemotherapy by combining Chinese herbal medicine with conventional anticancer drugs. It will also provide the scientific basis for taking a more comprehensive system biology-based approach in studying Chinese herbal medicine as well as other herbal medicines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA154295-02
Application #
8555271
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Project Start
2011-09-15
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$532,600
Indirect Cost
$42,427
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Guan, Fulan; Lam, Wing; Hu, Rong et al. (2018) Majority of Chinese Medicine Herb Category ""Qing Re Yao"" Have Multiple Mechanisms of Anti-inflammatory Activity. Sci Rep 8:7416
Tan, Hor-Yue; Wang, Ning; Lam, Wing et al. (2018) Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer 17:43
Sun, Jiehuan; Herazo-Maya, Jose D; Huang, Xiu et al. (2018) Distance-correlation based gene set analysis in longitudinal studies. Stat Appl Genet Mol Biol 17:
Lam, Wing; Ren, Yongshen; Guan, Fulan et al. (2018) Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Front Pharmacol 9:1324
Chao, Jung; Dai, Yuntao; Cheng, Hao-Yuan et al. (2017) Improving the Concentrations of the Active Components in the Herbal Tea Ingredient, Uraria crinita: The Effect of Post-harvest Oven-drying Processing. Sci Rep 7:38763
Liu, Yiyi; Zhao, Hongyu (2017) Variable importance-weighted Random Forests. Quant Biol 5:338-351
Sun, Jiehuan; Herazo-Maya, Jose D; Kaminski, Naftali et al. (2017) A Dirichlet process mixture model for clustering longitudinal gene expression data. Stat Med 36:3495-3506
Lin, Zhixiang; Wang, Tao; Yang, Can et al. (2017) On joint estimation of Gaussian graphical models for spatial and temporal data. Biometrics 73:769-779
Sun, Jiehuan; Warren, Joshua L; Zhao, Hongyu (2017) A Bayesian semiparametric factor analysis model for subtype identification. Stat Appl Genet Mol Biol 16:145-158
Zhu, Ruoqing; Zhao, Ying-Qi; Chen, Guanhua et al. (2017) Greedy outcome weighted tree learning of optimal personalized treatment rules. Biometrics 73:391-400

Showing the most recent 10 out of 51 publications